New blood test could improve pancreatic cancer outcomes
Researchers from the University of Pennsylvania and Mayo Clinic have developed a blood test that detects pancreatic cancer with high accuracy, especially in early stages, filling a critical screening gap.
The test, developed by University of Pennsylvania Perelman School of Medicine, Philadelphia, and Mayo Clinic, Rochester, Minnesota researchers, fills a gap in pancreatic ductal adenocarcinoma screening as “there are no current screening methods to do so.” It merges aminopeptidase N (ANPEP) and polymeric immunoglobin receptor (PIGR) with CA19-9 and THBS2 to detect all stages of pancreatic cancer. Specifically, “91.9% of the time for all stages combined at a false positive rate of 5% in non-cases” and 87.5% for early-stage I and II.
